Figure 1.
Figure 1. Cumulative incidence of tMDS/tAML following tositumomab and iodine I131 tositumomab for patients with relapsed/refractory NHL.

Cumulative incidence of tMDS/tAML following tositumomab and iodine I131 tositumomab for patients with relapsed/refractory NHL.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal